---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-045740"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:51:58.281535+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Organovo closes FXR program sale to Lilly; expects reduced spend and runway into FY2026

## Summary
- FXR program sold to Lilly; upfront payments received with future milestone payments anticipated.
- Overall expenditures expected to decrease due to elimination of FXR-related clinical, regulatory, and IP costs.
- Cash runway projected through end of FY2026; additional milestone payments could extend runway.
- Plans to leverage 3D human cellular IBD models to replicate FXR success with another therapeutic opportunity.
- Full-year FY2025 financial results expected on or about June 6-10, 2025.

## SEC filing metadata
- accession: 0000950170-25-045740
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000095017025045740/0000950170-25-045740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000095017025045740/onvo-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-045740
- JSON: https://secwatch.observer/filing/0000950170-25-045740.json
- Plain text: https://secwatch.observer/filing/0000950170-25-045740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.